The Social Health Insurance (It’s Health) reported that the budget for the purchase of drugs for cancer treatment was doubled, which went from S/ 37 million in 2021 to more than S/ 76 million in 2022, of which almost fifty%.
In addition, to date it has been possible to distribute more than 5 million units of pharmaceutical products valued at more than S/ 35.4 million, which has made it possible to provide chemotherapy treatment to cancer patients nationwide.
The investment made it possible to reinforce the supply of oncology pharmaceutical products in hospitals and other health establishments of the 30 service and assistance networks that EsSalud has throughout the country.
EsSalud’s Strategic Goods Supply Center (Ceabe) specified that the drugs include cyclophosphamide, filgrastrim, mesna, daunorubicin and fludarabine.
Likewise, he highlighted that EsSalud managed to supply 67 of the 69 oncological pharmaceutical products included in the centralized request for this year, which represents 97% of all drugs.
The Ceabe indicated that in the next few days another batch of fludarabine, bleomycin and ifosfamide will be entering hospital warehouses, in order to boost the stock of these products that will allow meeting demand at the national level.
Social Security pointed out that the current management has been adopting a series of actions to guarantee the supply of cancer drugs that are scarce or discontinued in the local and international market, due to the COVID-19 pandemic.
Likewise, the authorities of the institution hold regular meetings with associations and relatives of cancer patients in order to find a solution to the problems they present in the treatment of their minor children.
“EsSalud has been reinforcing the actions and allocating the necessary resources to guarantee the continuity of the supply of these products in order to provide timely treatment to our insured population diagnosed with cancer.”
